All the publications authored by Dr. Giovannetti (until June 2016)

Journals indexed in PubMed

(see also: www.scopus.com)

  1. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy. Leon LG, Funel N, Peters GJ, Avan A, Vistoli F, Boggi U, GIOVANNETTI E. Clin Cancer Res 2016 [Epub ahead of print]
  2. cMET exon 14 skipping: from the structure to the clinic. Van Der Steen N, GIOVANNETTI E, Pauwels P, Peters GJ, Hong DS, Cappuzzo F, Hirsch FR, Rolfo C. J Thorac Oncol 2016 [Epub ahead of print]
  3. Recent developments in the use of immunotherapy in non-small cell lung cancer. Santarpia M, GIOVANNETTI E, Rolfo C, Karachaliou N, González-Cao M, Altavilla G, Rosell R. Expert Rev Respir Med. 2016 May 5. [Epub ahead of print]
  4. Bioinformatic analysis reveals pancreatic cancer molecular subtypes specific to the tumor and the microenvironment. Le Large TY, Mato Prado M, Krell J, Bijlsma MF, Meijer LL, Kazemier G, Frampton AE, GIOVANNETTI E. Expert Rev Mol Diagn. 2016 [Epub ahead of print]
  5. Prospective Validation of microRNA Signatures for Detecting Pancreatic Malignant Transformation in Endoscopic-Ultrasound Guided Fine-Needle Aspiration Biopsies. Frampton AE, Krell J, Mato Prado M, Gall TMH, Abbassi-Ghadi N, Del Vecchio Blanco G, Funel N, GIOVANNETTI E, Castellano L, Habib NA, Vlavianos P, Stebbing J, Jiao LR. Oncotarget 2016 Apr 12 [Epub ahead of print]
  6. Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology:  a PAMM-EORTC perspective. Ciccolini J, Serdjebi C; Peters GJ, GIOVANNETTI E. Cancer Chem Pharmacol 2016 Mar 23. [Epub ahead of print]
  7. Feasibility of cell-free circulating tumor DNA testing for lung cancer. Santarpia M, Karachaliou N, González-Cao M, Altavilla G, GIOVANNETTI E, Rosell R. Biomark Med. 2016;10:417-30.
  8. The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer. Passiglia F, Caparica R, GIOVANNETTI E, Giallombardo M, Listi A, Diana P, Cirrincione G, Caglevic C, Raez LE, Russo A, Rolfo C. Exp Opin Invest New Drugs 2016;25:385-92.
  9. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Klionsky DA, GIOVANNETTI E, et al. Autophagy 2016;12:1-222.
  10. On the pharmacogenetics of non-small cell lung cancer treatment. Santarpia MC, Rolfo C, Peters GJ, Leon LG, GIOVANNETTI E. Expert Opin Drug Metab Toxicol. 2016;12:307-17.
  11. Prognostic and predictive role of thymidylate synthase expression in lung cancer: the debate is still open. GIOVANNETTI E, Zucali PA, Rolfo C, Assaraf YG, Peters GJ. J Clin Oncol 2016;34:511-2.
  12. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib. Muller IB, de Langen AJ, Honeywell RH, GIOVANNETTI E, Peters GJ. Exp Rev Anticancer Ther 2016;16:147-57.
  13. MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma – a step towards personalized therapy. Garajová I, Funel N, Fiorentino M, Agostini V, Ferracin M, Negrini M, Frassineti GL, Gavelli G, Frampton AE, Biasco G, GIOVANNETTI E. Clin Epigenetics 2015; 7:129.
  14. C-Met as a target for personalized therapy. Garajová I, GIOVANNETTI E, Biasco G, Peters GJ. Transl Oncogenomics 2015;Suppl.1:13-31
  15. Circulating microRNAs as diagnostic biomarkers for pancreatic cancer. Le Large TYS, Meijer LL, Mato Prado M, Kazemier G, Frampton AE, GIOVANNETTI E. Exp Rev Mol Diagn 2015;15(12):1525-9.
  16. Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation of ERK/Akt/mTOR. Verbrugge SE, Al M, Assaraf YG, Kammerer S, Chandrupatla DMSH, Honeywell R, Musters RPJ, GIOVANNETTI E, O’Toole T, Scheffer GL, Krige DG, de Gruijl TD, Niessen HWM, Lems WF, Kramer PA, Scheper RJ, Cloos J, Ossenkoppele GJ, Peters GJ, Jansen G. Oncotarget 2015 [Epub ahead of print]
  17. Entrectinib: A potent new TRK, ROS1, and ALK inhibitor–a therapeutic opportunity not only for Non-Small Cell Lung Cancer. Rolfo C, Ruiz R, GIOVANNETTI E, Gil-Bazo I, Peeters M, Raez L. Exp Opin Invest New Drugs 2015;24:1493-500.
  18. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. De Mattos-Arruda L Bottai G, Nuciforo PG, Di Tommaso L, GIOVANNETTI E, Peg V, Losurdo A, Pérez-Garcia J, Masci G, Corsi F, Cortés J, Seoane J, Calin GA, Santarpia L. Oncotarget 2015; 6(35):37269-80.
  19. Unraveling the complexity of autophagy: potential therapeutic applications in Pancreatic Ductal Adenocarcinoma. Gomez Mellado V, GIOVANNETTI E, Peters GJ. Sem Cancer Biol 2015;35:11-9
  20. Phase I clinical trial to determine the feasibility and maximum tolerated dose of panitumumab to standard gemcitabine-based chemoradiation in locally advanced pancreatic cancer. van Zweeden AA, van der Vliet HJ, Wilmink JW, Meijerink MR, Meijer OWM, Bruynzeel AME, van Tienhoven G, Giovannetti E, Kazemier G, Jacobs MAJM, Verheul HMW. Clin Cancer Res 2015 [Epub ahead of print]
  21. NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor. Galvani E, Sun J, Leon LG, Sciarrillo R, Narayan RS, Sjin RTT, Lee K, Ohashi K, Heideman DAM, Alfieri RR, Heynen GJ, Bernards R, Smit EF, Pao W, Peters GJ, Giovannetti E. Oncotarget 2015 [Epub ahead of print]
  22. microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: a meta-analysis. Frampton AE, Krell J, Jamieson NB, Gall TMH, Giovannetti E. Funel N, Mato Prado M, Krell D, Habib NA, Castellano L, Jiao LR, Stebbing J. Eur J Cancer 2015;51:1389-404.
  23. Usefulness of measuring microRNAs in bile and plasma for pancreatic ductal adenocarcinoma (PDAC) diagnosis. Le Large TYS, Frampton AE, Meijer L, Stebbing J, Kazemier G, Giovannetti E. Am J Gastroenterol 2015;110:768-9.
  24. MicroRNAs in Cancer Management: Big Challenges for Small Molecules. Gandellini P, Giovannetti E, Nicassio F. BioMed Research International 2015;2015:982156.
  25. Platinum-Induced Neurotoxicity and Preventive Strategies: Past, Present, and Future. Avan A, Postma TJ, Ceresa C, Avan A, Cavaletti G, Giovannetti E, Peters GJ. Oncologist 2015;20:411-32.
  26. Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of Docetaxel in Non-Small-Cell Lung Cancer (NSCLC) Patients. Vasile E, Tibaldi C, D’Incecco A, Leon LG, Giovannetti E. J Cancer Res Clin Oncol. 2015;141:1189-94.
  27. The EGFR pathway regulates BCRP expression in NSCLC cells: role of Erlotinib. Porcelli L, Giovannetti E, Jansen G, Assaraf YG, Scheffer GL, Kathman I, Azzariti A, Paradiso A, Peters GJ. Curr Drug Targets. 2014;15(14):1322-30.
  28. Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells. Leon LG, Gemelli M, Sciarrillo R, Avan A, Funel N, Giovannetti E. Curr Drug Targets. 2014;15(14):1331-40.
  29. New Strategies And Applications For Drugs Targeting EGFR and C-Met. Giovannetti E, Leon LG. Curr Drug Targets. 2014;15(14):1261-2
  30. AKT1 and SELP polymorphisms predict the risk of developing cachexia in pancreatic cancer patients. Avan A, Avan A, Le Large TYS, Mambrini A, Funel N, Maftouh M, Ghayour-Mobarhan M, Cantore M, Boggi U, Peters GJ, Pacetti P, GIOVANNETTI E. PLoS ONE 2014;9(9):e108057.
  31. Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer. Garajova I, Le Large TY, Frampton AE, Rolfo C, Voortman J, GIOVANNETTI E. BioMed Research International 2014;678401
  32. Genetic variation: Effect on prostate cancer. Sissung TM, Price DK, Del Re M, Ley AM, Giovannetti E, Figg WD, Danesi R. Biochim Biophys Acta. 2014;1846(2):446-456.
  33. Calcium/magnesium infusion for oxaliplatin-induced neuropathy: protective or not? Avan A, Avan A, GIOVANNETTI E, Peters GJ. J Clin Oncol 2014 [Epub ahead of print]
  34. On the use of pharmacogenetics in cancer treatment and clinical trials. Robert J, Valérie Le Morvan V, GIOVANNETTI E, Peters GJ. Eur J Cancer 2014;50(15):2532-2543.
  35. Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/β-catenin signalling in pancreatic adenocarcinoma. Maftouh M, Belo AI, Avan A, Funel N, Peters GJ, GIOVANNETTI E,* van Die I.* Oncotarget 2014; 30;5(14):5335-49. (*these authors equally contributed to the study)
  36. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. Rolfo C, GIOVANNETTI E, Hong DS, Bivona T, Raez L, Bronte G, Buffoni L, Reguart N, Santos E, Germonpré P, Taron M, Passiglia F, Van Meerbeeck JP, Russo A, Peeters M, Bazo IG, Pauwels P, Rosell R. Cancer Treat Rev 2014;40(8):990-1004.
  37. Impact of MicroRNAs in Resistance to Chemotherapy and Novel Targeted Agents in Non-Small Cell Lung Cancer. Rolfo C, Fanale D, Hong DS, Tsimberidou AM, Piha-Paul SA, Pauwels P, Van Meerbeeck JP, Caruso S, Bazan V, Cicero G, Russo A, GIOVANNETTI E. Curr Pharm Biotechnol. 2014; 15(5):475-85.
  38. SNPs in PI3K–PTEN–mTOR and Brain Metastases in NSCLC – Letter. Avan A, Maftouh M, Avan A, Tibaldi C, Zucali PA, GIOVANNETTI E. Clin Cancer Res 2014; 20(13):3623-4.
  39. A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients. Maftouh M, Avan A, Funel N, Paolicchi E, Vasile E, Pacetti P, Vaccaro V, Faviana P, Campani D, Caponi S, Mambrini A, Boggi U, Cantore M, Milella M, Peters GJ, Reni M, GIOVANNETTI E. Pharmacogenomics 2014;15:609-18.
  40. A microRNA meta-signature for pancreatic ductal adenocarcinoma. Frampton AE, GIOVANNETTI E, Jamieson NB, Krell J, Gall TM, Stebbing J, Jiao LR, Castellano L. Expert Rev Mol Diagn. 2014;14:267-71.
  41. CYB5A and autophagy-mediated cell death in pancreatic cancer. GIOVANNETTI E, Giaccone G. Autophagy 2014;10:697-8.
  42. CYB5A role in pancreatic cancer prognosis and autophagy modulation. GIOVANNETTI E,* Wang Q,* Avan A, Funel N, Lagerweij T, Lee JH, Caretti V, van der Velde A, Boggi U, Wang Y, Vasile E, Peters GJ, Wurdinger T, Giaccone G. JNCI – J Natl Cancer Inst. 2014;106(1):djt346. (*these authors equally contributed to the study)
  43. miRNAs Co-operatively Inhibit a Network of Tumor Suppressor Genes to Promote Pancreatic Tumor Growth and Progression. Frampton AE,* Castellano L,* Colombo T, GIOVANNETTI E, Krell J, Jacob J, Pellegrino L, Roca-Alonso L, Funel N, Gall TMH, Di Giorgio A, Fulci V, Britton DJ, Ahmad R, Habib NH, Knösel T, Coombes TC, Stebbing J, Jiao LR. Gastroenterology 2014;146:268-277 (*these authors equally contributed to the study)
  44. Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia. Maftouh M, Avan A, Sciarrillo R, Granchi C, Leon LG, Rani R, Funel N, Smid K, Honeywell R, Boggi U, Minutolo F, Peters GJ, GIOVANNETTI E. Br J Cancer 2014;110:172-82.
  45. Clinical application of pharmacogenetics of non-small cell lung cancer (NSCLC): time to “work it out”? Galvani E, Toffalorio F, Peters GJ, Pas TD, GIOVANNETTI E. Curr Pharm Des. 2014;20:3863-74.
  46. MET as a potential therapeutic target for the treatment of upper gastrointestinal cancers: characterization of novel c-Met inhibitors for therapeutic intervention Avan A, Maftouh M, Funel N, Ghayour-Mobarhan M, Boggi U, Peters GJ, GIOVANNETTI E. Curr Medicinal Chem 2014;21:975-89.
  47. Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. Bronte G, Rolfo C, GIOVANNETTI E, Cicero G, Pauwels P, Passiglia F, Castiglia M, Rizzo S, Lo Vullo F, Fiorentino E, Van Meerbeeck J, Russo A. Crit Rev Hematol Oncol 2014;89(2):300-13.
  48. Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification. La Monica S, Caffarra C, Saccani F, Galvani E, Galetti M, Fumarola C, Bonelli M, Cavazzoni A, Cretella D, Sirangelo R, Tiseo M, Ardizzoni A, GIOVANNETTI E, Petronini PG, Alfieri RR. PLoS ONE 2013;8:e78656. (§co-corresponding author)
  49. Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma. Avan A, Caretti V, Funel N, Galvani E, Maftouh M, Honeywell RJ, Lagerweij T, Van Tellingen O, Campani D, Fuchs D, Verheul HM, Schuurhuis GJ, Boggi U, Peters GJ, Würdinger T, GIOVANNETTI E. Cancer Res 2013;73:6745-56.
  50. Serum miR-1290 as a marker of pancreatic cancer – Letter. Frampton AE, Krell J, Kazemier G, GIOVANNETTI E. Clin Cancer Res 2013; 19:5250-1.
  51. USP1 deubiquitinase: cellular functions, regulatory mechanisms and emerging potential as target in cancer therapy. García-Santisteban I, Peters GJ, GIOVANNETTI E, Rodríguez JA. Mol Cancer 2013;12:91.
  52. One marker does not fit all: additional translational and validation studies are needed to identify faithful predictors of pemetrexed activity in mesothelioma. GIOVANNETTI E, Peters GJ, Zucali PA. J Thor Cancer 2013;8:e79-80
  53. Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography. Frings V, Van der Veldt AAM, Boellaard R, Herder GJM, GIOVANNETTI E, Honeywell R, Peters GJ, Thunnissen E, Hoekstra OS, Smit EF. PLoS ONE 2013;8:e63705.
  54. Gender, Cytidine Deaminase, and 5-Aza/Decitabine–Letter. Ciccolini J, Peters GJ, GIOVANNETTI E. Clin Cancer Res 2013;19:3105.
  55. Distinct miRNA profiles are associated with malignant transformation of pancreatic cystic tumors revealing potential biomarkers for clinical use. Frampton AE, Gall TM, GIOVANNETTI E, Stebbing J, Castellano L, Jiao LR, Krell J. Expert Rev Mol Diagn. 2013;13:325-9.
  56. Molecular mechanisms underlying the role of microRNAs in resistance to Epidermal Growth Factor Receptor-targeted agents and novel therapeutic strategies for treatment of Non-Small-Cell Lung Cancer. Maftouh M, Avan A, Galvani E, Peters GJ, GIOVANNETTI E. Crit Rev Oncogenesis 2013;18:317-26. (5th Most Downloaded Article of this journal: http://www.begellhouse.com/journals/critical-reviews-in-oncogenesis.html)
  57. An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: Implications for adjuvant treatment. Avan A, Maftouh M, GIOVANNETTI E. Cancer 2013; 119:2662-3.
  58. MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC cells that involves RIP1 and caspase-8 and is mediated by Mcl-1. Azijli K, Yuvaraj S, van Roosmalen I, Flach K, GIOVANNETTI E, Peters GJ, de Jong S, Kruyt FAE. Apoptosis 2013;18:851-60.
  59. Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back. Avan A, Pacetti P, Reni M, Milella M, Vasile E, Mambrini A, Vaccaro V, Caponi S, Cereda S, Peters GJ, Cantore M, GIOVANNETTI E. Int J Cancer 2013;133:1016-22.
  60. Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in Non-Small Cell Lung Cancer. Galvani E,* GIOVANNETTI E,* Saccani F, Cavazzoni A, Leon LG, Dekker H, Alfieri R, Carmi C, Mor M, Ardizzoni A, Petronini PG, Peters GJ. Neoplasia 2013;15:61-72. (*these authors equally contributed to the study)
  61. Chemotherapy, targeted agents, antiemetics and growth-factors in human milk: how should we counsel cancer patients about breastfeeding? Pistilli B, Bellettini G, GIOVANNETTI E, Codacci-Pisanelli G, Azim HA Jr., Sarno MA, Peccatori FA. Cancer Treat Rev 2013;39:207-11.
  62. The Good, the Bad and the Ugly: a Tale of MiR-101, MiR-21 and MiR-155 in Pancreatic Intraductal Papillary Mucinous Neoplasms. Caponi S, Funel N, Frampton AE, Mosca F, Santarpia L, Van der Velde A, Jiao LR, De Lio N, Falcone A, Kazemier G, Mejer GA, Verheul HM, Vasile E, Peters GJ, Boggi U, GIOVANNETTI E. Ann Oncol 2013;24:734-41.
  63. Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer. Avan A, Quint K, Nicolini F, Funel N, Frampton AE, Maftouh M, Pelliccioni S, Schuurhuis GJ, Peters GJ, GIOVANNETTI E. Curr Pharm Design 2013;19:940-50.
  64. Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells. GIOVANNETTI E, Labots M, Dekker H, Galvani E, Lind JSW, Sciarrillo R, Honeywell R, Smit EF, Verheul HM, Peters GJ. Curr Pharm Design 2013;19:927-39.
  65. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: current status and future perspective in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer. Galvani E, Alfieri R, GIOVANNETTI E, Cavazzoni A, La Monica S, Galetti M, Fumarola C, Bonelli M, Mor M, Tiseo M, Peters GJ, Petronini PG, Ardizzoni A. Curr Pharm Design 2013;19:818-32.
  66. Development of new molecular agents targeting key signalling pathways activated by growth factors in human cancer. GIOVANNETTI E, Peters GJ. Curr Pharm Design 2013;19:807.
  67. Defining a prognostic molecular profile for ductal adenocarcinoma of the pancreas highlights known key signaling pathways. Frampton AE, Krell J, GIOVANNETTI E, Krell D, Stebbing J, Castellano L, Jiao LR. Expert Rev Anticancer Ther. 2012;12:1275-8.
  68. Role of miRNAs in the response to anticancer therapy. Frampton AE, Krell J, GIOVANNETTI E, Jiao LR, Stebbing J. Pharmacogenomics 2012;13:1663-6.
  69. High-throughput microRNA (miRNAs) arrays unravel the prognostic role of miR-211 in pancreatic cancer. GIOVANNETTI E, Van der Velde AG, Funel N, Vasile E, Perrone V, Leon LG, De Lio N, Avan A, Caponi S, Pollina LE, Gallá V, Sudo H, Falcone A, Campani D, Boggi U, Peters GJ. PLoS ONE 2012; 7:e49145.
  70. Research Highlights: Highlights from the latest articles in pharmacogenomics of irinotecan/cisplatin toxicity. Peters GJ, GIOVANNETTI E. Pharmacogenomics 2012; 13:1445-7.
  71. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib. Erdem L,* GIOVANNETTI E,* Leon LG, Honeywell R, Peters GJ. Curr Top Med Chem 2012;12:1649-59 (*these authors equally contributed to the study)
  72. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin. Tiseo M*, GIOVANNETTI E*, Tibaldi C*, Camerini A, Di Costanzo F, Barbieri F, Burgers JA, Vincent A, Peters GJ, Smit EF, Ardizzoni A. Lung Cancer 2012;78:92-9. (*these authors equally contributed to the study)
  73. EGFR-targeted therapy in NSCLC: role of germline polymorphisms in outcome and toxicity. Galvani E, Peters GJ, GIOVANNETTI E. Future Oncol 2012;8:1015-29.
  74. Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer (NSCLC): a changing landscape? GIOVANNETTI E, Toffalorio F, De Pas T, Peters GJ. Pharmacogenomics 2012:13:1073-86.
  75. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A (DZNeP) with gemcitabine in pancreatic cancer cells. Avan A, Crea F, Paolicchi E, Funel N, Galvani E, Marquez VE, Honeywell RJ, Danesi R, Peters GJ GIOVANNETTI E. Mol Cancer Ther 2012; 11:1735-46; selected in the Highlights of the issue
  76. Methylation status of TFAP2E and chemoresistance in colorectal cancer. GIOVANNETTI E, Codacci-Pisanelli G, Peters GJ. New Engl J Med 2012;366:966
  77. Molecular targets of gemcitabine action: rationale for development of novel drugs and drug combinations. Elnaggar M, GIOVANNETTI E, Peters GJ. Curr Pharm Design 2012;18:2811-29
  78. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. GIOVANNETTI E, Erozenci A, Smit J, Danesi R, Peters GJ. Crit Rev Hematol Oncol 2012; 81:103-22 (#10 among the most 25 downloaded articles in Crit Rev Hematol Oncol from January to February 2011)
  79. The only thing I know is that I know nothing: 5-FU in human milk. Peccatori FA, GIOVANNETTI E, Pistilli B, Bellettini G, Codacci-Pisanelli G, Losekoot N, Curigliano G, Azim HA Jr, Goldhirsh A, Peters GJ. Ann Oncol 2012;23:543-4
  80. Loss of 18q22.3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer. Lee JH, GIOVANNETTI E, Hwang JH, Petrini I, Wang Q, Voortman J, Wang Y, Steinberg SM, Funel N, Meltzer P, Wang Y, Giaccone G. Clin Cancer Res 2012;18:524-33
  81. Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine/platinum-treated advanced Non-Small-Cell lung cancer patients. Tibaldi C,* GIOVANNETTI E,* Tiseo M,* Leon LG, D’Incecco A, Losekoot N, Bartolotti M, Honeywell R, Cappuzzo F, Ardizzoni A, Peters GJ. Ann Oncol 2012;23:670-7 (*these authors equally contributed to the study)
  82. Association between DNA repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. GIOVANNETTI E,* Pacetti P,* Reni M,* Leon GL, Mambrini A, Vasile E, Ghidini M, Funel N, Lucchesi M, Cereda S, Peters GJ, Cantore M. Pharmacogenomics 2011;12:1641-52 (*these authors equally contributed to the study)
  83. Preclinical emergence of vandetanib as a potent antitumor agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin. GIOVANNETTI E, Zucali PA, Assaraf YG, Leon LG, Smid K, Alecci C, Giancola F, Destro A, Gianoncelli L, Lorenzi E, Roncalli M, Santoro A, Peters GJ. Br J Cancer 2011;105:1542-53
  84. N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation. Granchi C, Roy S, De Simone A, Salvetti I, Tuccinardi T, Martinelli A, Macchia M, Lanza M, Betti L, Giannaccini G, Lucacchini A, GIOVANNETTI E, Sciarrillo R, Peters GJ, Minutolo F. Eur J Med Chem 2011;46:5398-407
  85. Thymidylate synthase inhibitors for non-small cell lung cancer. Galvani E, Peters GJ, GIOVANNETTI E. Exp Opin Invest Drugs 2011; 20:1343-56
  86. Critical role of laser microdissection for genetic, epigenetic and proteomic analyses in pancreatic cancer. Funel N,* GIOVANNETTI E,* Pollina LE, Del Chiaro M, Mosca F, Boggi U, Campani D. Exp Rev Mol Diagn 2011;11:695-701 (*these authors equally contributed to the study)
  87. DNA copy number profiles correlate with outcome in colorectal cancer patients treated with fluoropyrimidine/antifolate-based regimens. León LG,* GIOVANNETTI E,* Smid K, Hanauske AR, Giaccone G, Peters GJ. Curr Drug Metab 2011;12:956-65. (*these authors equally contributed to the study)
  88. Antiproliferative effects of novel aliphatic acetogenin analogs against aggressive solid tumor cell lines. León LG, GIOVANNETTI E, Alecci C, Giancola F, Funel N, Zucali P, Peters GJ, Padrón JM. In Vivo 2011;25:203-7
  89. Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against tumors. Granchi C, Roy S, Macchia M, Tuccinardi T, Martinelli A, Lanza M, Betti L, Giannaccini G, Lucacchini A, Funel N, León LG, GIOVANNETTI E, Peters GJ, Palchaudhuri R, Hergenrother PJ, Minutolo F. J Med Chem 2011; 54:1599-1612
  90. Optimizing pemetrexed-gemcitabine combination in patients with advanced non-small cell lung cancer: a pharmacogenetic approach. De Pas T, Toffalorio F, GIOVANNETTI E, Radice D, Russo F, Angeli I, Calamai G, Spitaleri G, Catania C, Noberasco C, Milani A, Pelosi G, Danesi R, de Braud F. J Thorac Oncol 2011,6:768-73
  91. Loss of Heterozygosity (LOH) status of D9S105 marker is associated with down-regulation of Kruppel-Like Factor 4 (KLF4) expression in Pancreatic Ductal Adenocarcinoma and PanINs. Funel N, Morelli M, GIOVANNETTI E,° Del Chiaro M, Polina LE, Mosca F, Boggi U, Cavazzana A, Campani D. Pancreatology 2011;11:30-42 (°Corresponding author)
  92. The impact of ABCG2 polymorphisms on clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. Lemos C,* GIOVANNETTI E,* Zucali PA, Assaraf YG, Scheffer GL, van der Straaten T, D’Incecco A, Falcone A, Santoro A, Giaccone G, Tibaldi C, Peters GJ. Pharmacogenomics 2011;12:159-70 (*these authors equally contributed to the study)
  93. Thymidylate Synthase (TS) and Excision Repair Cross-Complementing Group-1 (ERCC-1) as predictors of response in malignant pleural mesothelioma patients treated with pemetrexed and carboplatin. Zucali PA, GIOVANNETTI E, Destro A, Ceresoli GL, Gianoncelli L, Lorenzi E, De Vincenzo F, Simonelli M, Thunissen E, Giordano L, Roncalli M, Peters GJ, Santoro A. Clin Cancer Res 2011;17:2581-90
  94. Inherited germ-line T790M mutations and somatic EGFR- mutations in Non-Small Cell Lung cancer patients. Tibaldi C*, GIOVANNETTI E*, Vasile E, Boldrini L, Gallegos-Ruiz MI, Bernardini I, Incensati R, Danesi R, Cappuzzo F, Peters GJ, Fontanini G. (*these authors equally contributed to the study) J Thorac Oncol 2011;6:395-6
  95. Correlation of basal EGFR expression with pancreatic cancer grading but not with clinical outcome after gemcitabine-based treatment. Funel N, Vasile E, Del Chiaro M, Boggi U, Falcone A, Campani D, Scarpa A, GIOVANNETTI E. Ann Oncol 2011;22(2):482-4
  96. Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer. GIOVANNETTI E,* Erdem L,* Olcay E, Leon LG, Peters GJ. Front Biosci 2011;16:116-30 (*these authors equally contributed to the study)
  97. Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Hormone Refractory Prostate Cancer (HRPC) patients. Pastina I*, GIOVANNETTI E*, Chioni A, Sissung TM, Crea F, Orlandini C, Price DK, Cianci C, Figg WD, Ricci S, Danesi R. BMC Cancer 2010;10:511 (*these authors equally contributed to the study)
  98. Differences of Gene Expression in Non-Small Cell Lung Cancer: Are Histology, Tumor Site, and Methodology Relevant? Toffalorio F, De Pas T, GIOVANNETTI E. J Thorac Oncol 2010;5:1310-1
  99. MicroRNA-21 as a biomarker for benefit from adjuvant therapy in resectable pancreatic adenocarcinoma. Hwang JH,* Voortman V,* GIOVANNETTI E,* Steinberg SM, Leon GL, Kim YT, Funel N, Park JK, Kim MA, Kang GH, Kim SW, Del Chiaro M, Peters GJ, Giaccone G. PLoS ONE 2010;5:e10630 (*these authors equally contributed to the study)
  100. MicroRNA-21 (miR-21) in pancreatic adenocarcinoma (PDAC): correlation with clinical outcome and pharmacological aspects underlying its role in the modulation of gemcitabine activity. GIOVANNETTI E,* Funel N,* Peters GJ, Del Chiaro M, Erozenci LA, Leon GL, Groen A, Pollina LE, Danesi R, Campani D, Verheul HM, Boggi U. Cancer Res 2010;70:4528-38 (*these authors equally contributed to the study)
  101. New tricks for old biomarkers: thymidylate synthase expression as a predictor of pemetrexed activity in mesothelioma. Zucali PA,* GIOVANNETTI E,* Assaraf YG, Ceresoli GL, Peters GJ, Santoro A. Ann Oncol 2010; 21:1560-1 (*these authors equally contributed to the study)
  102. A multicenter, phase II study of erlotinib and sorafenib in chemotherapy naïve patients with advanced non-small cell lung cancer. Lind JSW, Dingemans AMC, Groen HJM, Thunnissen FB, Bekers O, Heideman D, Honeywell R, GIOVANNETTI E, Postmus P, Smit EF. Clin Cancer Res 2010; 16:3078-87
  103. A simple and selective method for determination of several tyrosine kinase inhibitors by liquid chromatography tandem mass spectrometry. Honeywell R, Yarzadah K, GIOVANNETTI E, Losekoot N, Smit EF, Tibaldi C, Walraven M, Lind J, Verheul HM, Peters GJ. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878:1059-68
  104. Impact of Cytidine Deaminase Polymorphisms on Toxicity after Gemcitabine: The Question Is Still Ongoing. GIOVANNETTI E,* Tibaldi C,* Falcone A, Danesi R, Peters GJ. J Clin Oncol 2010; 28(14):e221-2 (*these authors equally contributed to the study)
  105. Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small-cell lung cancer patients treated with gefitinib. GIOVANNETTI E*, Zucali P*, Peters GJ, Cortesi F, D’Incecco A, Smit EF, Falcone A, Burgers S, Santoro A, Danesi R, Giaccone G, Tibaldi C (*these authors equally contributed to the study). Mol Cancer Ther 2010, 9:581-93; selected in the Highlights of the issue
  106. Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cells. Nannizzi S, Veal GJ, GIOVANNETTI E°, Mey V, Ricciardi S, Del Tacca M, Danesi R. Cancer Chemother Pharmacol 2010; 66:547-58 (°Corresponding author)
  107. Expression of gemcitabine and cisplatin-related genes in NSCLC. Toffalorio F*, GIOVANNETTI E*, De Pas T, Danesi R, Radice D, Pelosi G, Manzotti M, Minocci D, Spaggiari L, Spitaleri G, Noberasco C, Catania C, Boselli S, De Braud F. Pharmacogenomics J 2010; 10:180-90 (*these authors equally contributed to the study)
  108. Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer. GIOVANNETTI E, Honeywell R, Hanauske AR, Tekle C, Kuenen B, Sigmond J, Lahn M, Giaccone G, and Peters GJ. Curr Drug Targets 2010;11:12-28.
  109. Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of colorectal cancer patients. Mauritz R, GIOVANNETTI E, Beumer IJ, van Groeningen CJ, Pinedo HM, Peters GJ. Clin Colorectal Cancer 2009;8:146-54.
  110. Epigenetic mechanisms of irinotecan resistance in colorectal cancer cells. Crea F, GIOVANNETTI E, Cortesi F, Mey V, Nannizzi S, Gallegos-Ruiz M, Ricciardi S, Del Tacca M, Peters GJ, Danesi R. Mol Cancer Ther 2009;8:1964-73.
  111. Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer (NSCLC) and peripheral blood mononuclear cells (PBMCs). Ceresa C*, GIOVANNETTI E*, Voortman J, Laan AC, Honeywell R, Giaccone G, Peters GJ. Mol Cancer Ther 2009; 8:1026-32 (*these authors equally contributed to the study)
  112. Pharmacogenomics in non-small-cell lung cancer chemotherapy. Danesi R, Pasqualetti G, GIOVANNETTI E, Crea F, Altavilla G, Del Tacca M, Rosell R. Adv Drug Deliv Rev 2009;61:408-17
  113. Cellular folate status modulates the expression of BCRP and MRP multidrug transporters in cancer cell lines from different origins. Lemos C, Kathmann I, GIOVANNETTI E, Beliën JAM, Scheffer GL, Calhau C, Jansen G, Peters GJ. Mol Cancer Ther 2009;8:655-64
  114. Pharmacogenomics of gemcitabine in non-small cell lung cancer (NSCLC) and other solid tumors. Danesi R, Altavilla G, GIOVANNETTI E, Rosell R. Pharmacogenomics 2009;10:69-80.
  115. ABCG2 is a determinant of gefitinib resistance in Epidermal Growth Factor Receptor-expressing cells: impact of cellular folate status on biological activity. Lemos C, Ietje Kathmann I, GIOVANNETTI E, Calhau C, Jansen G, Peters GJ. Br J Cancer 2009; 100:1120-7
  116. Pharmacological rationale for timing and tailoring of prophylactic G-CSF therapy in oncology. Crea F*, GIOVANNETTI E*, Zinzani PL, Danesi R. Crit Rev Hematol Oncol 2009; 72:21-44 (*these authors equally contributed to the study)
  117. Molecular pathways involved in the synergistic interaction of the PKC-beta inhibitor enzastaurin with the antifolate pemetrexed in non-small-cell lung cancer cells. Tekle C*, GIOVANNETTI E*, Sigmond J, Graaf J, Smid K, Peters GJ. Br J Cancer 2008; 99:750-9. (*these authors equally contributed to the study)
  118. Folate deprivation induces BCRP (ABCG2) expression and mitoxantrone resistance in CaCo-2 cells. Lemos C, Kathmann I, GIOVANNETTI E, Dekker H, Scheffer GL, Calhau C, Jansen G, Peters GJ. Int J Cancer 2008;123:1712-20
  119. Role of cMET expression in non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Zucali PA, Gallegos Ruiz M, GIOVANNETTI E, Destro A, Garcia M, Floor K, Ceresoli GL, Rodriguez JA, Roncalli M, Santoro A, Giaccone G. Ann Oncol 2008;19:1605-12.
  120. Laser microdissection improves gene expression analysis of pharmacogenetics determinants in pancreas cancer. Funel N, GIOVANNETTI E, Del Chiaro M, Mey V, Boggi U, Pollina LE, Nannizzi S, Ricciardi S, Del Tacca M, Danesi R, Mosca F, Bevilacqua G, Campani D. Lab Invest 2008;88:773-84
  121. Correlation of cytidine deaminase and DNA repair genes polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Tibaldi C*, GIOVANNETTI E*, Vasile E, Mey V, Nannizzi S, Laan AC, Orlandini C, Ricci S, Di Marsico R, Antonuzzo A, Del Tacca M, Peters GJ, Falcone A, Danesi R. Clin Cancer Res 2008; 14:1797-803 (*these authors equally contributed to the study)
  122. Molecular mechanisms underlying the synergistic interaction of erlotinib, an EGFR tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small cell lung cancer (NSCLC) cells. GIOVANNETTI E, Lemos C, Tekle C, Smid K, Nannizzi S, Rodriguez JA, Danesi R, Giaccone G, Peters GJ. Mol Pharmacol 2008; 73:1290-300
  123. Methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate synthase promoter (TSER) polymorphisms in Indonesian children with and without Leukemia. GIOVANNETTI E, Ugrasena DG, Supriyadi E, Vroling L, Azzarello A, de Lange D, Peters GJ, Veerman AJP, Cloos Leuk Res 2008; 2:19-24.
  124. The role of pharmacogenetics in adjuvant treatment of non-small-cell lung cancer. Danesi R, Pasqualetti G, GIOVANNETTI E, Del Tacca M. J Thorac Oncol 2007; 2(5 Suppl):S27-30
  125. Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels. GIOVANNETTI E*, Backus HHJ*, Wouters D, Ferreira CG, van Houten VMM, Brakenhoff RH, Poupon MF, Azzarello A, Pinedo HM, Peters Br J Cancer 2007; 96:769-75 (*these authors equally contributed to the study)
  126. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells. GIOVANNETTI E, Mey V, Loni L, Nannizzi S, Barsanti G, Savarino G, Del Tacca M, Danesi R. Pharmacol Res 2007; 5:343-9
  127. Synergistic antitumor activity of ZD6474, an inhibitor of VEGFR and EGFR signaling, with gemcitabine and ionizing radiation against pancreatic cancer. Bianco C*, GIOVANNETTI E*, Ciardiello F, Mey V, Nannizzi S, Tortora G, Troiani T, Pasqualetti F, Eckhardt G, de Liguoro M, Del Tacca M, Raben D, Cionini L, Danesi R. Clin Cancer Res 2006; 12:7099-107 (*these authors equally contributed to the study); selected in the Highlights of the issue
  128. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. GIOVANNETTI E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S, Orlandini C, Boggi U, Campani D, Del Chiaro M, Iannopollo M, Bevilacqua G, Mosca F, Danesi R. Cancer Res 2006; 66:3928-35
  129. In vitro studies on gemcitabine combinations with other antiblastics. GIOVANNETTI E, Danesi R, Mey V, Nannizzi S, Pasqualetti G, Del Tacca M. Ann Oncol 2006; 17 Suppl 5:v17-9
  130. Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. GIOVANNETTI E, Mey V, Nannizzi S, Pasqualetti G, Del Tacca M, Danesi R. Mol Cancer Ther 2006; 5:1387-95
  131. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. Mey V, GIOVANNETTI E°, De Braud F, Nannizzi S, Curigliano G, Verweij F, De Cobelli O, Pece S, Del Tacca M, Danesi R. Br J Cancer 2006; 95:289-97 (°Corresponding author)
  132. Interaction between gemcitabine and topotecan in human non-small cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile. GIOVANNETTI E, Mey V, Danesi R, Basolo F, Barachini S, Deri M, Del Tacca M. Br J Cancer 2005; 92:681-9
  133. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small cell lung cancer cells. GIOVANNETTI E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, Danesi R. Mol Pharmacol 2005; 68:110-8
  134. Prolonged fixed dose rate infusion of gemcitabine with autologous hemopoietic support in advanced pancreatic adenocarcinoma. Bengala C, Guarneri V, GIOVANNETTI E, M Lencioni, Fontana E, V Mey, Fontana A, Boggi U, Del Chiaro M, Danesi R, Ricci S, Mosca F, Del Tacca M, Conte PF. Br J Cancer 2005; 93:35-40
  135. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. GIOVANNETTI E, Mey V, Danesi R, Mosca I, Del Tacca M. Clin Cancer Res 2004; 10:2936-46
  136. Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small cell lung cancer. Fogli S, Danesi R, De Braud F, De Pas T, Curigliano G, GIOVANNETTI E, Del Tacca M. Ann Oncol 2001; 12:1553-9
  137. Design, Synthesis, and Characterization of the Antitumor Activity of Novel Ceramide Analogues. Macchia M, Barontini S, Bertini S, Di Bussolo V, Fogli S, GIOVANNETTI E, Grossi E, Minutolo F, and Danesi R. J Med Chem 2001, 44:3944-4000

 

Abstracts – Conference proceedings in PubMed

  1. Integrated molecular analysis to investigate the role of microRNAs in pancreatic tumour growth and progression. Frampton AE, Castellano L, Colombo T, GIOVANNETTI E, Krell J, Jacob J, Pellegrino L, Roca-Alonso L, Funel N, Gall TM, Ahmad R, Habib NA, Knösel T, Stebbing J, Jiao LR. Lancet. 2015;385 Suppl 1:S37.
  2. MiR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behaviour of pancreatic cancer cells. Maftouh M, Avan A, Funel N, Frampton AE, Fiuji H, Pelliccioni S, Castellano L, Galla’ V, Peters GJ, GIOVANNETTI E. Nucleosides Nucleotides Nucleic Acids. 2014;33:384-393.
  3. Selection of the Best Blood Compartment to Measure Cytidine Deaminase Activity to Stratify for Optimal Gemcitabine or Cytarabine Treatment. Peters GJ, Honeywell RJ, Maulandi M, GIOVANNETTI E., Losekoot N, Etienne-Grimaldi MC, Milano G, Serdjebi C, Ciccolini J; for the EORTC-Pharmacology and Molecular Mechanism Group. Nucleosides Nucleotides Nucleic Acids. 2014;33:403-412.
  4. Characterization of and Protection from Neurotoxicity Induced by Oxaliplatin, Bortezomib and Epothilone-B. Ceresa C, Avan A, GIOVANNETTI E , Geldof AA, Avan A, Cavaletti G, Peters GJ. Anticancer Res 2014;34:517-23.
  5. Predictive role of repair enzymes in the efficacy of cisplatin combinations in pancreatic and lung cancers. Peters GJ, Avan A, Gallegos Ruiz M, Avan A, Orsini V, GIOVANNETTI E , Smit EF. Anticancer Res 2014;34:435-42.
  6. A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma. Paolicchi E, Pacetti P, GIOVANNETTI E, Mambrini A, Orlandi M, Crea F, Romani AA, Tartarini R, Danesi R, Peters GJ, Cantore M. Oncol Lett. 2013;6:1487-1491.
  7. Regulation of Deoxycytidine Kinase Expression and Sensitivity to Gemcitabine by Micro-RNA 330 and Promoter Methylation in Cancer Cells. Hodzic J, GIOVANNETTI E, Calvo BD, Adema AD, Peters GJ. Nucleosides Nucleotides Nucleic Acids. 2011;30:1214-22
  8. Determination of the Phosphorylated Metabolites of Gemcitabine and of Difluorodeoxyuridine by LC/MS-MS. Honeywell RJ, GIOVANNETTI E, Peters GJ. Nucleosides Nucleotides Nucleic Acids. 2011;30:1203-13
  9. Tyrosine kinase inhibitors: multi-targeted or single-targeted? Broekman F, GIOVANNETTI E, Peters GJ. World J Clin Oncol 2011, 2:80-93
  10. Analysis of drug interactions. Bijnsdorp IV, GIOVANNETTI E, Peters GJ. Methods Mol Biol. 2011;731:421-34.
  11. Promoter methylation of deoxycytidine kinase in cancer cells. Peters GJ, Hodzic J, Ortega B, GIOVANNETTI E, Adema AD, Broekhuizen R, Kaspers GJ, Hubeek I. Nucleosides Nucleotides Nucleic Acids 2010;29:408-413
  12. Study of apoptosis induction and deoxycytidine kinase/cytidine deaminase modulation in the synergistic interaction of a novel ceramide analog and gemcitabine in pancreatic cancer cells. GIOVANNETTI E, Leon GL, Bertini S, Macchia M, Minutolo F, Funel N, Alecci C, Giancola F, Danesi R, Peters GJ. Nucleosides Nucleotides Nucleic Acids 2010; 29:419-26
  13. Single nucleotide polymorphisms and clinical outcome in patients with biliary tract carcinoma treated with epirubicin, cisplatin and capecitabine. Pacetti P*, GIOVANNETTI E*, Mambrini A, Nannizzi S, Del Tacca M, Cantore M, Danesi R. Anticancer Res 2009; 29:1835-40. (*these authors equally contributed to the study)
  14. Functional inactivity and mutations of p53 affect differently the sensitivity to 5-fluorouracil and antifolate inhibitors of thymidylate synthase (TS) by altering TS levels in colorectal cancer cells. GIOVANNETTI E, Backus HHJ, Wouters D, Peters GJ. Nucleosides Nucleotides Nucleic Acids 2008, 27:740-45
  15. Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples. GIOVANNETTI E, Laan AC, Vasile E, Tibaldi C, Nannizzi S, Ricciardi S, Danesi R, Falcone A, Peters GJ. Nucleosides Nucleotides Nucleic Acids 2008;27:720-25
  16. Expression of the nucleoside transporters hENT1 and hCNT1 in pediatric acute myeloid leukaemia. Hubeek I, Peters GJ, GIOVANNETTI E, Broekhuizen AJF, Pastor-Anglada M, Casado JF, Gibson BE, Creutzig U, Kaspers GJL. Nucleosides Nucleotides Nucleic Acids 2008;27:787-93
  17. Variously substituted (phosphonoacetamido)oxy analogues of geranylgeranyl diphosphate (GGdP) as GGdP-transferase (GGTase) inhibitors and antiproliferative agents. Minutolo F, Asso V, Bertini S, Betti L, Ciriaco M, Danesi R, Gervasi G, Ghilardi E, GIOVANNETTI E, Giannaccini G, Placanica G, Prota G, Rapposelli S, Macchia M. Med Chem 2005; 1:239-44
  18. Conformationally restrained ceramide analogues: effects of lipophilic modification on the antiproliferative activity. Macchia M, Antonello M, Bertini S, Di Bussolo V, Fogli S, GIOVANNETTI E, Minutolo F, Rapposelli S, Danesi R. Farmaco 2003, 58:85-9
  19. Ceramide analogues in apoptosis: a new strategy for anticancer drug development. Macchia M, Bertini S, Fogli S, GIOVANNETTI E, Minutolo F, Rapposelli S, Danesi R. Farmaco 2003; 58:205-11

 

Other Publications (Journals not indexed in PubMed)

 

  1. MiRNAs and Their Interference with the Main Molecular 
Mechanisms Responsible for Drug Resistance in Pancreatic 
Cancer. Garajova I, GIOVANNETTI E, Caponi S, van Zweeden A, Peters GJ. Curr Pharmacol Reports 2015;1:4:223-32.
  2. Polymorphisms Correlated with the Clinical Outcome of Locally Advanced or Metastatic Colorectal Cancer Patients Treated with ALIRI vs FOLFIRI. Barcelos A, GIOVANNETTI E,° de Jonge R, Maftooh M, Griffioen P, Hanauske AR, Peters GJ. Pteridines 2013;24:69-79 (°Corresponding author)
  3. Thymidylate synthase inhibitors for thoracic tumors. Peters GJ, Galvani E, Jansen G, Assaraf Y, GIOVANNETTI E. Pteridines 2013;24:57-67
  4. Drug Delivery and Drug Resistance: EGFR-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Olcay E, GIOVANNETTI E, Peters GJ. The Open Lung Cancer Journal 2010; 3:26-33
  5. Role of Pharmacodynamics, Pharmacogenetic and Pharmacogenomics Biomarkers of Cancer Chemotherapy with Antifolates. Peters GJ, Honeywell RH, Leon LG, van Groeningen CJ, Jansen G, Ylstra B, Meijer GA, GIOVANNETTI E. Pteridines 2010, 20:115-27

 

 Conference proceedings on journals online

  1. Clinical and Translational Results of a Phase II Randomized Trial of Maintenance Sunitinib or Observation in Metastatic Pancreatic Adenocarcinoma. Belli C, Cereda S, Novarino A, Milella M, Passardi A, Di Lucca G, Mambrini A, Ferrari L, Danova M, Bergamo F, Franceschi E, GIOVANNETTI E, Rovati R, Gallà V, Balzano G, Ariotti R, Villa E, Reni M. J Pancreas (Online) 2012 Sep 20; 13(5 Suppl):551.
  2. PTEN and MIR-21 Expression in IPMN and PDAC. Alvino A, Botta L, Denaro M, Pollina LE, Perrone V, De Lio N, Caniglia F, Boggi U, Campani D, Funel N, GIOVANNETTI E. J Pancreas (Online) 2012 Sep 20; 13(5 Suppl):580.
  3. Synergistic Interaction of Novel Lactate Dehydrogenase Inhibitors with Gemcitabine in Hypoxic Models of Pancreatic Cancer. GIOVANNETTI E, Sciarrillo R, Granchi C, Leon LG, Funel N, Macchia M, Avan A, Minutolo F, Peters GJ. J Pancreas (Online) 2011 Oct 11; 12(5):513.
  4. Significant Association Between DNA Repair Polymorphisms and Survival in Pancreatic Cancer Patients Treated with Gemcitabine/Platinum Combination Chemotherapy. GIOVANNETTI E, Reni M, Pacetti P, Mambrini A, Vasile E, Lucchesi M, Ghidini M, Funel N, Avan A, Cereda S, Cantore M, Peters GJ. J Pancreas (Online) 2011 Oct 11; 12(5):514.
  5. MicroRNA-21: An Oncomir Under the Spotlight as a Potential Biomarker of Clinical Outcome and Determinant of Chemoresistance in Pancreatic Cancer. Giovannetti E, Funel N, Vasile E, Del Chiaro M, Leon LG, Erozenci LA, Pollina LE, Falcone A, Danesi R, Verheul HM, Boggi U, Peters GJ, Campani D. J Pancreas (Online) 2010 Sep 20; 11(5 Suppl):509.
  6. Molecular Mechanisms Underlying the Synergistic Interaction of the Novel Anticancer Drug Ukrain with Gemcitabine in Preclinical Models of Pancreatic Cancer. Funel N, Giovannetti E, Nowicky W, Pollina LE, Del Chiaro M, Nowicky B, Mosca F, Peters GJ, Campani D, Boggi U. J Pancreas (Online) 2010 Sep 20; 11(5 Suppl):524-525.
  7. Loss of Heterozygosity (LOH) Status of D9S105 Marker Is Associated with Down-Regulation of Kruppel-Like Factor 4 (KLF4) Expression in Pancreatic Ductal Adenocarcinoma and PanINs. Funel N, Morelli M, Giovannetti E, Pollina LE, Del Chiaro M, Bevilacqua G, Mosca F, Cavazzana A, Campani D, Boggi U J Pancreas (Online) 2010 Sep 20; 11(5 Suppl):506.
  8. Significant association between DNA repair polymorphisms and survival in pancreatic cancer patients treated with polychemotherapeutic regimens. Giovannetti E, Pacetti P, Reni M, Alecci C, Giancola F, Ghidini M, Mambrini A, Leon GL, Cereda S, Funel N, Orlandi M, Rezzonico S, Del Chiaro M, Danesi R, Peters GJ, Cantore M. J Pancreas (Online) 2009;10(5 Suppl):599.
  9. Selective Effect of Ukrain in Primary Pancreatic Tumor Cell Cultures. Funel N, Giovannetti E, Nowicky W, Pollina LE, Del Chiaro M, Peters GJ, Mosca F, Boggi U, Campani D. J Pancreas (Online) 2009;10(5 Suppl):616-617.
  10. Laser Microdissection (LMD) and Primary Cell Cultures Improve Pharmacogenetic Analysis in Pancreatic Adenocarcinoma, Allowing the Use of Gene Expression Levels and WHO Grading as Prognostic Markers. Funel N, Giovannetti E, Del Chiaro M, Pollina LE, Mey V, Boggi U, Salem AF, Nannizzi S, Del Tacca M, Bevilacqua G, Mosca F, Danesi R, Campani D. J Pancreas (Online) 2008;9(6 Suppl):812.
  11. Genes Involved in Gemcitabine Activity: Pancreas Cancer vs. Primary Cell Cultures. Funel N, Giovannetti E, Campani D, Pollina LE, Di Cristofano C, Mey V, Menicagli M, Nannizzi S, Morelli M, De Nisi MC, Danesi R, Del Chiaro M, Boggi U, Del Tacca M, Mosca F, Cavazzana A, Bevilacqua G. J Pancreas (Online) 2006;7(5 Suppl):534.
  12. Pharmacogenetics of Gemcitabine in Pancreatic Cancer. Giovannetti E, Mey V, Danesi R, Del Chiaro M, Funel N, Boggi U, Orlandini C, Campani D, Iannopollo M, Nannizzi S, Ricci S, Bevilacqua G, Mosca F, Del Tacca M.. J Pancreas (Online) 2004;6(5 Suppl):488-489.

 

Book chapters

  1. Pancreatic cancer: Prevention, Detection, Treatment and translational research. Avan A, Maftouh M, Ghayour-Mobarhan M, Peters GJ, GIOVANNETTI E. Gastrointestinal Cancers: Prevention, Detection and Treatment, Nova Publisher 2016, in press
  2. CYB5A (Cytochrome B5 Type A (microsomal)). Gomez VE, Avan A, Peters GJ, GIOVANNETTI E. Atlas Genet Cytogenet Oncol Haematol. January 2016. Link: www.atlasgeneticsoncology.org
  3. The role of microRNAs in resistance to current pancreatic cancer treatment: translational studies and basic protocols for extraction and PCR analysis. Garajová I, Le Large TY, GIOVANNETTI E, Kazemier G, Biasco G, Peters GJ. Methods in Molecular Biology – Cancer Drug Resistance, in press
  4. Pharmacology and clinical development of new molecularly targeted agents. Chapter 3: Targeted Therapies for Solid Tumors. GIOVANNETTI E, Galvani E (editors, Antonio Russo, Rafael Rosell, Christian Diego Rolfo), Springer Science Ed, New York, US, in press
  5. EZH2 (enhancer of zeste homolog 2). Avan A, Maftouh M, Fiuji H, GIOVANNETTI E, Peters GJ. Atlas Genet Cytogenet Oncol Haematol. March 2014
  6. USP1 (ubiquitin specific peptidase 1). García-Santisteban I, Peters GJ, Rodriguez JA, GIOVANNETTI E. Atlas Genet Cytogenet Oncol Haematol. October 2013. http://AtlasGeneticsOncology.org/Genes/USP1ID43072ch1p31.html
  7. MIR211 (microRNA 211). Avan A, Maftouh M, Peters GJ, GIOVANNETTI E. Atlas Genet Cytogenet Oncol Haematol. May 2013.http://AtlasGeneticsOncology.org/Genes/MIR211ID50533ch15q13.html
  8. Analysis of drug interactions. Chapter 4.25: Cancer Cell Culture, Bijnsdorp IV, GIOVANNETTI E, Peters GJ. 2011, Humana Press Inc., in PubMed as Analysis of drug interactions. Bijnsdorp IV, GIOVANNETTI E, Peters GJ. Methods Mol Biol. 2011;731:421-34.
  9. Proteomics and genomics (Proteomica e genomica) Chapter in: Proteomics, genomics and development of new drugs. Danesi R, Di Paolo A, GIOVANNETTI E, Bocci G, Del Tacca M. 2007. Ed. Poletto Editore srl, Milano, Italy
  10. Molecular Therapy in Oncology (Terapia Molecolare in Oncologia) Chapter 4: Pharmacogenetics and Pharmacogenomics. Danesi R, GIOVANNETTI E, Pasqualetti G, Del Tacca M (editors, Dino Amadori and Carlo Maria Croce) 2005, Ed. Poletto Editore srl, Milano, Italy
FacebookGoogle+LinkedInTumblrTwitterPrintFriendlyShare